Summary
FGFR2 genetic translocations are frequent in cholangiocarcinoma, yet despite initial sensitivity to FGFR inhibitors in clinic, patients quickly become resistant to targeted therapies. The work published by Goyal and colleagues demonstrates that acquisition of gatekeeper mutations in FGFR2 and intra-tumoral heterogeneity drive resistance in patients with FGFR2-translocated intrahepatic cholangiocarcinoma, which will have important implications for management of the disease in clinic.
Editorial
Oncogenic chromosomal rearrangements in the fibroblast growth factor receptors (FGFRs) present a potential therapeutic target, with translocations in FGFR2 found most frequently in cholangiocarcinoma (1,2) and translocations in FGFR3 prevalent in bladder and glioblastoma (2) . Preclinical models of these fusion proteins have demonstrated sensitivity to FGFR inhibitors, and recent data from early phase clinical trials substantiated these findings in the clinic (3) (4) (5) . However the extent of these translocations as true oncogenic drivers, and the potential mechanisms of resistance to therapy, have previously only been investigated preclinically. Goyal et al (6) demonstrate FGFR2 translocations in intrahepatic cholangiocarcinoma (ICC) are classic oncogene drivers, with response to FGFR inhibition in the clinic followed by development of common gatekeeper mutations in FGFR2 resulting in clinical resistance.
Cholangiocarcinoma has historically been dichotomised by anatomical location into intra-and extra-hepatic subtypes. Recent developments in genomic and transcriptomic technologies have revealed fundamental molecular differences between these anatomic sub-sites, reflecting distinct aetiologies (7) . Intrahepatic cholangiocarcinoma, a disease with growing incidence for yet unknown reasons, In this issue of Cancer Discovery, Goyal and colleagues report on a proposed mechanism of resistance to FGFR inhibition in three patients treated with NVP-BGJ398. Although the number of patients studied is small, these patients revealed consistent acquisition of gatekeeper mutations in FGFR2 and polyclonal resistance reflective of diverse intra-tumoural genetic heterogeneity in cholangiocarcinoma.
Using molecular barcoded sequencing on progression plasma DNA and tumour, they describe the acquisition of polyclonal FGFR2 mutations, with a gatekeeper p.V564F mutation found in all three patients. Mutations at this residue had been identified as potential gatekeeper mutation in prior preclinical studies (8, 9) , and this study confirms the importance of p.V564 residue in mediating resistance to targeted therapy. In total, the study identified three FGFR2 mutations that were common fundamental question that the current study raises is the utility of post-progression biopsies to evaluate mechanisms of resistance in the face of gross tumour heterogeneity. As the sensitivity of circulating DNA sequencing increases, this tool may become the primary method through which the genomic evolution of tumours is evaluated, as the limitations imposed by the spatial boundaries of biopsies may needlessly limit our capacity to fully comprehend the complexity of heterogeneous tumours.
